Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer

BACKGROUND: Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. Plk1 is upregulated in many tumor types including colorectal cancer (CRC) and portends a poor prognosis. TAK-960 is an ATP-competitive Plk1 inhibitor that has demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Klauck, Peter J., Bagby, Stacey M., Capasso, Anna, Bradshaw-Pierce, Erica L., Selby, Heather M., Spreafico, Anna, Tentler, John J., Tan, Aik Choon, Kim, Jihye, Arcaroli, John J., Purkey, Alicia, Messersmith, Wells A., Kuida, Keisuke, Gail Eckhardt, S., Pitts, Todd M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800287/
https://www.ncbi.nlm.nih.gov/pubmed/29402316
http://dx.doi.org/10.1186/s12885-018-4036-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800287/
https://www.ncbi.nlm.nih.gov/pubmed/29402316
http://dx.doi.org/10.1186/s12885-018-4036-z

Ejemplares similares